 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | QN-030a / Qihan Biotech
New P1 trial: Natural Killer(NK) Cell Therapy in r/r AML (clinicaltrials.gov) - Dec 27, 2022
P1, N=18, Recruiting, Sponsor: Zhejiang University
- | QN-030a / Qihan Biotech
New P1 trial, Minimal residual disease: Natural Killer(NK) Cell Therapy for AML Minimal Residual Disease (clinicaltrials.gov) - Nov 1, 2022
P1, N=18, Recruiting, Sponsor: Institute of Hematology & Blood Diseases Hospital